---
aliases: [CRSP, CRISPR]
---
#actor #genomics #geneediting #biotech #usa #public

**CRISPR Therapeutics** — Gene editing pioneer. Casgevy first FDA-approved CRISPR therapy. Vertex partnership.

---

## Why CRISPR Therapeutics matters

| Metric | Value |
|--------|-------|
| Ticker | CRSP |
| Market cap | ~$4B |
| Founded | 2013 |
| Key product | **Casgevy** (first CRISPR therapy) |
| Partner | [[Vertex]] |

---

## Casgevy (exa-cel)

**First FDA-approved CRISPR therapy** (Dec 2023)

| Indication | Status |
|------------|--------|
| Sickle cell disease (SCD) | **FDA approved** |
| Beta thalassemia (TDT) | **FDA approved** |

### Global approvals (as of 2025)

| Region | Status |
|--------|--------|
| US | Approved |
| UK | Approved |
| EU | Approved |
| Canada | Approved |
| Switzerland | Approved |
| Saudi Arabia | Approved |
| UAE | Approved |
| Bahrain | Approved |
| Italy | Reimbursement agreement |

### How it works

1. Patient's stem cells extracted
2. CRISPR edits BCL11A gene
3. Edited cells reinfused
4. Produces fetal hemoglobin (HbF)
5. Functional cure for SCD/TDT

---

## Commercial progress

| Metric | Status |
|--------|--------|
| Active treatment sites | 50+ (NA, EU, Middle East) |
| Patient momentum | Strong heading into late 2025 |
| Addressable patients (US) | ~16,000 SCD |

**Pricing:** One-time gene therapy, premium pricing expected.

---

## Pipeline

| Program | Target | Stage |
|---------|--------|-------|
| Casgevy | SCD, TDT | **Approved** |
| CTX110 | CD19 (cancer) | Phase 1 |
| CTX130 | CD70 (cancer) | Phase 1 |
| CTX112 | CD19 (next-gen) | Phase 1 |
| In vivo programs | Various | Preclinical |

---

## Vertex partnership

| Terms | Details |
|-------|---------|
| Partner | [[Vertex]] |
| Structure | Co-development, profit share |
| Commercial | Vertex leads US/EU |
| Economics | ~50/50 profit split |

---

## Competitive landscape

| Company | Approach | Status |
|---------|----------|--------|
| **CRISPR Therapeutics** | Ex vivo CRISPR | Approved |
| Intellia | In vivo CRISPR | Phase 3 |
| Beam Therapeutics | Base editing | Clinical |
| Editas | CRISPR (ocular) | Clinical |
| Prime Medicine | Prime editing | Early |
| Bluebird Bio | Lentiviral (Lyfgenia) | Approved (SCD) |

---

## Investment case

**Bull:**
- First-mover: Only approved CRISPR therapy
- Vertex partnership de-risks commercial
- Functional cure = transformative
- Pipeline expansion (oncology, in vivo)
- Global expansion underway

**Bear:**
- Complex manufacturing/logistics
- High treatment cost limits access
- Bluebird competition (Lyfgenia)
- Pipeline still early stage
- Vertex takes commercial lead

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | CRSP |
| Key product | Casgevy |
| Partner | Vertex |
| Focus | Gene editing therapeutics |

---

## Related

- [[Vertex]] — commercial partner
- [[Genomics]] — sector concept
- [[Biopharma]] — sector
- [[AI drug discovery]] — related trend

---

## Sources

- [FDA Casgevy Approval](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease)
- [CRISPR Clinical Trials 2025](https://innovativegenomics.org/news/crispr-clinical-trials-2025/)
- [Company IR](https://ir.crisprtx.com/)

*Created 2026-01-09*
